GlassScriptPhysician profile
Sherril M Rieux
NPI 1427144989
$2,220.99
in general payments reported to CMS, 2019-2025
13 companies · $148 in 2025
The $148 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $438 · 2020: $568 · 2021: $741 · 2022: $140 · 2023: $89.23 · 2024: $97.38 · 2025: $148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $334.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,656.68 | 2019-2022 | |
| Abbvie INC. | $126.94 | 2019-2023 | Mavyret |
| Intercept Pharmaceuticals, INC. | $89.96 | 2021-2025 | Ocaliva |
| Gilead Sciences, INC. | $79.60 | 2024-2025 | |
| Novo Nordisk INC | $66.22 | 2019-2024 | Wegovy |
| Madrigal Pharmaceuticals | $58.84 | 2025 | Rezdiffra |
| Takeda Pharmaceuticals U.S.A., INC. | $33.69 | 2025 | Entyvio |
| Lilly USA, LLC | $23.17 | 2023 | Mounjaro |
| Phathom Pharmaceuticals, INC. | $22.45 | 2024 | Voquezna |
| Evoke Pharma, INC. | $21.96 | 2021 | |
| Qol Medical, LLC | $15.17 | 2020 | |
| Redhill Biopharma INC. | $13.45 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $12.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherril Rieux listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.